Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013-2014).
Telavancin is approved in the United States and Europe for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia caused by Staphylococcus aureus. This study provides a current in vitro activity analysis for telavancin and comparators against 1353 United States S. aureus causing pneumonia in hospitalized patients during 2013-2014. Telavancin was found to exhibit potent activity (MIC90, 0.06μg/mL; 16-fold more active than vancomycin or linezolid) against all S. aureus isolates, including the HABP subset, multidrug-resistant isolates, and those less susceptible to vancomycin.
JMI Laboratories, North Liberty, IA, USA.
Leonard R
LR
Duncan
Theravance Biopharma US, Inc, South San Francisco, CA, USA.
Jennifer I
JI
Smart
JMI Laboratories, North Liberty, IA, USA.
Robert K
RK
Flamm
JMI Laboratories, North Liberty, IA, USA.
Helio S
HS
Sader
JMI Laboratories, North Liberty, IA, USA.
Ronald N
RN
Jones
JMI Laboratories, North Liberty, IA, USA. Electronic address: rodrigo-mendes@jmilabs.com.
Rodrigo E
RE
Mendes
D000617:Aminoglycosides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D006760:Hospitalization; D006801:Humans; D000077427:Lipoglycopeptides; D008826:Microbial Sensitivity Tests; D011023:Pneumonia, Staphylococcal / Q000382:microbiology* / Q000473:pathology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification*; D014481:United States
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000077427:Lipoglycopeptides; C487637:telavancin
Hospital-acquired pneumonia; Resistance; S. aureus; Surveillance; Telavancin